BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 9665148)

  • 1. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors.
    Gotlieb WH; Friedman E; Bar-Sade RB; Kruglikova A; Hirsh-Yechezkel G; Modan B; Inbar M; Davidson B; Kopolovic J; Novikov I; Ben-Baruch G
    J Natl Cancer Inst; 1998 Jul; 90(13):995-1000. PubMed ID: 9665148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
    Abeliovich D; Kaduri L; Lerer I; Weinberg N; Amir G; Sagi M; Zlotogora J; Heching N; Peretz T
    Am J Hum Genet; 1997 Mar; 60(3):505-14. PubMed ID: 9042909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer.
    Lu KH; Cramer DW; Muto MG; Li EY; Niloff J; Mok SC
    Obstet Gynecol; 1999 Jan; 93(1):34-7. PubMed ID: 9916952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
    Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
    Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
    Lehrer S; Fodor F; Stock RG; Stone NN; Eng C; Song HK; McGovern M
    Br J Cancer; 1998 Sep; 78(6):771-3. PubMed ID: 9743298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
    Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
    Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
    Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
    Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
    Roa BB; Boyd AA; Volcik K; Richards CS
    Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A family with three germline mutations in BRCA1 and BRCA2.
    Liede A; Metcalfe K; Offit K; Brown K; Miller S; Narod SA; Moslehi R
    Clin Genet; 1998 Sep; 54(3):215-8. PubMed ID: 9788724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An identical novel mutation in BRCA1 and a common haplotype in familial ovarian cancer in non-Ashkenazi Jews.
    Theodor L; Bar-Sade R; Kruglikova A; Ben-Baruch G; Risel S; Shiri-Sverdlov R; Hirsh Yechezkel G; Modan B; Papa MZ; Rechavi G; Friedman E
    Br J Cancer; 1998 Jun; 77(11):1880-3. PubMed ID: 9667663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
    Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
    Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
    Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
    Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
    Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
    Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer.
    Gotlieb WH; Chetrit A; Menczer J; Hirsh-Yechezkel G; Lubin F; Friedman E; Modan B; Ben-Baruch G;
    Gynecol Oncol; 2005 Jun; 97(3):780-3. PubMed ID: 15893369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
    Hodgson SV; Heap E; Cameron J; Ellis D; Mathew CG; Eeles RA; Solomon E; Lewis CM
    J Med Genet; 1999 May; 36(5):369-73. PubMed ID: 10353781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
    Ramus SJ; Fishman A; Pharoah PD; Yarkoni S; Altaras M; Ponder BA
    Eur J Surg Oncol; 2001 Apr; 27(3):278-81. PubMed ID: 11373105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of BRCA1/BRCA2 genes' contribution to breast cancer susceptibility in high risk Jewish Ashkenazi women.
    Distelman-Menachem T; Shapira T; Laitman Y; Kaufman B; Barak F; Tavtigian S; Friedman E
    Fam Cancer; 2009; 8(2):127-33. PubMed ID: 18798010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.